Diamant Elliott, Roumiguié Mathieu, Ingels Alexandre, Parra Jérôme, Vordos Dimitri, Bajeot Anne-Sophie, Chartier-Kastler Emmanuel, Soulié Michel, de la Taille Alexandre, Rouprêt Morgan, Seisen Thomas
Sorbonne Université, Department of Urology, GRC n°5 Predictive Onco-Urology, AP-HP, Pitié-Salpêtrière Hospital, 75013 Paris, France.
Department of Urology, CHU-Institut Universitaire du Cancer-Oncopôle, 31000 Toulouse, France.
Cancers (Basel). 2022 Aug 4;14(15):3797. doi: 10.3390/cancers14153797.
Purpose: The purpose of this study is to compare perioperative and oncological outcomes of upfront vs. delayed early radical cystectomy (eRC) for high-risk non-muscle-invasive bladder cancer (HR-NMIBC). Methods: All consecutive HR-NMIBC patients who underwent eRC between 2001 and 2020 were retrospectively included and divided into upfront and delayed groups, according to the receipt or not of BCG. Perioperative outcomes were evaluated and the impact of upfront vs. delayed eRC on pathological upstaging, defined as ≥pT2N0 disease at final pathology, was assessed using multivariable logistic regression. Recurrence-free (RFS), cancer-specific (CSS) and overall survival (OS) were compared between upfront and delayed eRC groups using inverse probability of treatment weighting (IPTW)-adjusted Cox model. Results: Overall, 184 patients received either upfront (n = 87; 47%) or delayed (n = 97; 53%) eRC. No difference was observed in perioperative outcomes between the two treatment groups (all p > 0.05). Pathological upstaging occurred in 55 (30%) patients and upfront eRC was an independent predictor (HR = 2.65; 95% CI = (1.23−5.67); p = 0.012). In the IPTW-adjusted Cox analysis, there was no significant difference between upfront and delayed eRC in terms of RFS (HR = 1.31; 95% CI = (0.72−2.39); p = 0.38), CSS (HR = 1.09; 95% CI = (0.51−2.34); p = 0.82) and OS (HR = 1.19; 95% CI = (0.62−2.78); p = 0.60). Conclusion: our results suggest similar perioperative outcomes between upfront and delayed eRC, with an increased risk of upstaging after upfront eRC that did impact survival, as compared to delayed eRC.
本研究旨在比较高危非肌层浸润性膀胱癌(HR-NMIBC)患者接受 upfront 与延迟早期根治性膀胱切除术(eRC)的围手术期及肿瘤学结局。方法:回顾性纳入 2001 年至 2020 年间接受 eRC 的所有连续性 HR-NMIBC 患者,并根据是否接受卡介苗(BCG)治疗分为 upfront 组和延迟组。评估围手术期结局,并使用多变量逻辑回归评估 upfront 与延迟 eRC 对病理分期升级(定义为最终病理检查时≥pT2N0 疾病)的影响。使用倾向评分加权(IPTW)调整的 Cox 模型比较 upfront 组和延迟组的无复发生存期(RFS)、癌症特异性生存期(CSS)和总生存期(OS)。结果:总体而言,184 例患者接受了 upfront(n = 87;47%)或延迟(n = 97;53%)eRC。两组治疗的围手术期结局无差异(所有 p > 0.05)。55 例(30%)患者出现病理分期升级,upfront eRC 是独立预测因素(HR = 2.65;95%CI =(1.23 - 5.67);p = 0.012)。在 IPTW 调整的 Cox 分析中,upfront 与延迟 eRC 在 RFS(HR = 1.31;95%CI =(0.72 - 2.39);p = 0.38)、CSS(HR = 1.09;95%CI =(0.51 - 2.34);p = 0.82)和 OS(HR = 1.19;95%CI =(0.62 - 2.78);p = 0.60)方面无显著差异。结论:我们的结果表明,upfront 与延迟 eRC 的围手术期结局相似,与延迟 eRC 相比,upfront eRC 后分期升级风险增加,且确实影响生存。